These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 15085287)
1. [Pancreatic cancer: a major challenge in oncology]. Fölsch UR; Schäfer H Med Klin (Munich); 2004 Apr; 99(4):183-4. PubMed ID: 15085287 [No Abstract] [Full Text] [Related]
2. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240 [TBL] [Abstract][Full Text] [Related]
4. Where and when does pancreatic carcinoma start? Lüttges J; Hahn S; Klöppel G Med Klin (Munich); 2004 Apr; 99(4):191-5. PubMed ID: 15085289 [TBL] [Abstract][Full Text] [Related]
5. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310 [TBL] [Abstract][Full Text] [Related]
6. Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Müerköster S; Arlt A; Sipos B; Witt M; Grossmann M; Klöppel G; Kalthoff H; Fölsch UR; Schäfer H Cancer Res; 2005 Feb; 65(4):1316-24. PubMed ID: 15735017 [TBL] [Abstract][Full Text] [Related]
7. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Kosuge T; Kiuchi T; Mukai K; Kakizoe T; Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736 [TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer and cancer screening programs: from nihilism to hope. Pezzilli R; Corinaldesi R; Morselli-Labate AM JOP; 2010 Nov; 11(6):654-5. PubMed ID: 21068511 [No Abstract] [Full Text] [Related]
9. Increasing survival rates of patients with pancreatic cancer by earlier identification. Greenhalf W; Neoptolemos JP Nat Clin Pract Oncol; 2006 Jul; 3(7):346-7. PubMed ID: 16826198 [No Abstract] [Full Text] [Related]
10. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. Stoecklein NH; Luebke AM; Erbersdobler A; Knoefel WT; Schraut W; Verde PE; Stern F; Scheunemann P; Peiper M; Eisenberger CF; Izbicki JR; Klein CA; Hosch SB J Clin Oncol; 2004 Dec; 22(23):4737-45. PubMed ID: 15570074 [TBL] [Abstract][Full Text] [Related]
11. [Selection of genes related to multidrug resistance of pancreatic ductal adenocarcinoma by microarray analysis]. Feng B; Zhao YP; Chen G; Zhang TP; Wu YD Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(23):1629-33. PubMed ID: 18453221 [TBL] [Abstract][Full Text] [Related]
12. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Xie K; Wei D; Huang S Cytokine Growth Factor Rev; 2006 Jun; 17(3):147-56. PubMed ID: 16516532 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Grützmann R; Boriss H; Ammerpohl O; Lüttges J; Kalthoff H; Schackert HK; Klöppel G; Saeger HD; Pilarsky C Oncogene; 2005 Jul; 24(32):5079-88. PubMed ID: 15897887 [TBL] [Abstract][Full Text] [Related]
14. Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer. Ghaneh P; Neoptolemos JP Surg Oncol Clin N Am; 2004 Oct; 13(4):567-87, vii-viii. PubMed ID: 15350935 [TBL] [Abstract][Full Text] [Related]
15. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Arnold NB; Ketterer K; Kleeff J; Friess H; Büchler MW; Korc M Cancer Res; 2004 May; 64(10):3599-606. PubMed ID: 15150118 [TBL] [Abstract][Full Text] [Related]
16. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. Delitto D; Vertes-George E; Hughes SJ; Behrns KE; Trevino JG World J Gastroenterol; 2014 Jul; 20(26):8458-70. PubMed ID: 25024602 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326 [TBL] [Abstract][Full Text] [Related]
18. Personalizing pancreatic cancer organoids with hPSCs. Zhang HC; Kuo CJ Nat Med; 2015 Nov; 21(11):1249-51. PubMed ID: 26540385 [No Abstract] [Full Text] [Related]
19. Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. McNamara MG Curr Probl Cancer; 2018; 42(1):8-11. PubMed ID: 29397186 [No Abstract] [Full Text] [Related]